ArticleEuropean journal of medical research2025
The impact of ultrasound contrast-enhanced fusion virtual navigation technology-guided microwave ablation (MWA) and standard MWA on the local tumor progression of hepatocellular carcinoma with unclear ultrasound images.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Combined imaging and serum biomarkers in CEUS-guided microwave ablation for hepatocellular carcinoma: A meta-analysis.Frontiers in oncology · 2025Pooled it
- [Ultrasound technology's new application in the diagnosis and treatment of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCompared the impact of ultrasound contrast-enhanced fusion virtual navigation technology-guided microwave ablation (MWA) and standard MWA on the local tumor progression of hepatocellular carcinoma with unclear ultrasound images, to explore the utility of virtual navigation ultrasound contrast-enhanced imaging.
methodsA retrospective analysis was conducted on clinical data from hepatocellular carcinoma patients admitted between June 2021 and August 2022, all of whom had liver lesions suggested by Computed Tomography (CT) or Magnetic Resonance (MR) but not visualized on 2D ultrasound. They underwent ultrasound contrast-enhanced fusion virtual navigation technology-guided microwave ablation and standard microwave ablation, and comparisons were made between the two groups in terms of general information, blood parameters, ultrasonic test, intraoperative indicators, ablation indicators, postoperative complications, recurrence indicators, local progression and long-term outcomes.
resultsThere were no significant differences in blood parameters, postoperative complications, and disease-free survival between the two groups. (P > 0.05). The ultrasound contrast-enhanced fusion virtual navigation technology-guided microwave ablation group had significantly higher lesion detection rate, ablation efficacy, proportion of safe margin > 5 mm, recurrence time and complete ablation rate compared to the standard microwave ablation group, with significantly lower ablation time, recurrence rate and residual disease at 1-month compared to conventional ablation and significant differences in local progression (P < 0.05).
conclusionUltrasound contrast-enhanced fusion virtual navigation, as a novel ultrasound contrast-enhanced technique, enabled the visualization of liver lesions that are indistinct on 2D ultrasound imaging, significantly enhancing lesion detection and microwave ablation efficiency. It also reduced local progression and recurrence rates, demonstrating significant clinical utility. Its advantages positioned it as a critical tool for precise ablation localization and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.